<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01851278</url>
  </required_header>
  <id_info>
    <org_study_id>IIA- 3131- AR</org_study_id>
    <nct_id>NCT01851278</nct_id>
  </id_info>
  <brief_title>Effectiveness Intraarticular Corticosteroid</brief_title>
  <official_title>Effectiveness and Tolerance Infiltration Intraarticular Corticosteroid According to Dose</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal University of São Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundação de Amparo à Pesquisa do Estado de São Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Federal University of São Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the small and large dose of corticosteroid used in
      intraarticular injection of wrist.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background / Objectives: The optimal dose of corticosteroid to be used in intraarticular
      injection is not well established. The objective of this study is to compare the
      effectiveness and tolerance in the medium-term between small and large dose of triamcinolone
      hexacetonide (TH) used in intraarticular injection (IAI) of medium size joint of patients
      with rheumatoid arthritis (RA). Materials/Methods: A controlled, randomized, prospective,
      double-blind study will be realized in patients with RA. It will be evaluated 60 wrists
      joints (representing medium size joints) from the outpatient clinics at the Rheumatology
      Division UNIFESP, Brazil. Inclusion criteria were: patients with established RA, age between
      18 and 65 years, disease modifying anti-rheumatic drugs (DMARDs) stable for at least 3
      months, synovitis in wrist with pain visual analogic scale (VAS) between 4 and 8cm. Patients
      with overlap syndromes, polyarticular synovitis, diabetes mellitus or uncontrolled
      hypertension and those with suspected local or systemic infection were excluded. Patients
      will be randomized (Clapboard randomization) in two groups of 30 patients each: group 1 (high
      dose) is injected with 40mg (2ml) of TH and group 2 (small dose) was injected 20mg (1ml).
      Only one joint is injected by patient (IAI blindly). Evaluation will be conducted by a
      blinded observer at five times: baseline (T0), one week (T1), four (T4), eight (T8) and
      twelve (T12) weeks and the following assessment instruments were used: visual analogue scale
      for pain and swollen (VAS 0-10cm); wrist goniometry; chronic disease activity index (CDAI).
      Side effects and related events were reported in a medical questionnaire. The level of
      statistical significance was 5%.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual analog scale (VAS)</measure>
    <time_frame>up to 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>chronic disease activity index (CDAI)</measure>
    <time_frame>up to 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>high dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intraarticular wrist injection of 40mg, 2ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>low dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intraarticular wrist injection of 20mg, 1ml.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triamcinolone hexacetonide</intervention_name>
    <description>High dose means 40mg or 2ml of triamcinolone hexacetonide</description>
    <arm_group_label>high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triamcinolone hexacetonide</intervention_name>
    <description>Low dose means 20mg or 1 ml of triamcinolone hexacetonide</description>
    <arm_group_label>low dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with established RA

          -  age between 18 and 65 years

          -  disease modifying anti-rheumatic drugs (DMARDs) stable for at least 3 months

          -  synovitis in wrist with pain visual analogic scale (VAS) between 4 and 8cm

        Exclusion Criteria:

          -  patients with overlap syndromes

          -  polyarticular synovitis

          -  diabetes mellitus or uncontrolled hypertension and those with suspected local or
             systemic infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniele F Pereira, MsC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidade Federal de São Paulo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universidade Federal de São Paulo</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>04024002</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniele F Pereira, doctor</last_name>
      <phone>55 11 55764239</phone>
      <email>danisfreitas22@yahoo.com.br</email>
    </contact>
    <investigator>
      <last_name>Daniele F Pereira, doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <results_reference>
    <citation>American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines: Guidelines for the management of rheumatoid arthritis. Arthitis Rheum 2002;46:328-46. Thiele K et al. Current use of glucocorticoids in patients with rheumatoid arthritis in Germany. Arthritis Rheum 2005;53:740-747. Habib GS et al. Local effects of intra-articular corticosteroids. Clin Rheumatol 2010;29:347-356. Konai MS et al. Monoarticular corticosteroid injection versus systemic administration in the treatment of rheumatoid arthritis patients: a randomized double-blind controlled study. Clin Exp Rheumatol 2009;27(2):214-21.</citation>
  </results_reference>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2013</study_first_submitted>
  <study_first_submitted_qc>May 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2013</study_first_posted>
  <last_update_submitted>May 9, 2013</last_update_submitted>
  <last_update_submitted_qc>May 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federal University of São Paulo</investigator_affiliation>
    <investigator_full_name>Daniele Freitas Pereira</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>injection</keyword>
  <keyword>arthritis</keyword>
  <keyword>corticosteroid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

